Scilex Holding Company filed a Form 8-K on November 20, 2026, disclosing that it received a Nasdaq deficiency notice on November 17, 2026, citing failure to meet the minimum market value of listed securities requirement for continued listing on the Nasdaq Capital Market.
Key Highlights
- Deficiency period: Scilex's market value of listed securities was below the $35 million minimum for 30 consecutive business days, from October 6, 2026 through November 16, 2026, according to the filing.
- Alternative standards not met: The notice indicated the company also does not meet the alternative continued listing standards under Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3), relating to minimum stockholders' equity and net income from continuing operations, respectively.
- No immediate trading impact: The filing states the notice has no immediate effect on listing or trading of common stock (NASDAQ:SCLX) or warrants (SCLXW) on the Nasdaq Capital Market.
- Compliance deadline: The company has 180 calendar days, until May 17, 2027, to regain compliance with the market value of listed securities requirement.
- Compliance threshold: To close the matter, the company's market value of listed securities must close at $35 million or more for a minimum of ten consecutive business days before the compliance date.
- No assurance provided: The filing states "there can be no assurance that the Company will be able to timely regain compliance with the MVLS Requirement by the Compliance Date."
Scilex Discloses Nasdaq Market Value Deficiency and 180-Day Cure Period
According to the Form 8-K filed November 20, 2026, Scilex Holding Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC on November 17, 2026. The notice stated that the company's market value of listed securities had remained below the $35 million minimum required by Nasdaq Listing Rule 5550(b)(2) for 30 consecutive business days, specifically the period from October 6, 2026 through November 16, 2026. The filing also noted that the company does not satisfy the alternative standards under Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3).
The filing reports that, under Nasdaq Listing Rule 5810(c)(3)(C), the company has been granted a 180-calendar-day compliance period ending May 17, 2027. During this window, if the company's market value of listed securities closes at $35 million or more for at least ten consecutive business days, Nasdaq will provide written confirmation of compliance and close the matter. The filing notes that Nasdaq may, at its discretion, require the company to satisfy the requirement for up to 20 consecutive business days before determining long-term compliance has been demonstrated.
If compliance is not regained by May 17, 2027, the filing states that Nasdaq will issue written notification that the company's securities are subject to delisting, at which point the company may appeal to a Nasdaq Hearings Panel. The company disclosed it "intends to monitor its MVLS and is evaluating available options to regain compliance," while cautioning that no assurance of timely compliance can be given. The Form 8-K was signed by Stephen Ma, Senior Vice President, Chief Operating Officer and Chief Financial Officer.
What Was Disclosed
Scilex Holding Company disclosed receipt of a Nasdaq deficiency notice for failure to maintain a $35 million market value of listed securities over 30 consecutive business days, with a compliance deadline of May 17, 2027, and no immediate effect on trading of SCLX or SCLXW.



Please wait processing your request...